
==== Front
Pediatr Nephrol
Pediatr Nephrol
Pediatric Nephrology (Berlin, Germany)
0931-041X
1432-198X
Springer Berlin Heidelberg Berlin/Heidelberg

39008116
6415
10.1007/s00467-024-06415-4
Original Article
Infant urinary tract infection in Sweden — A national study of current diagnostic procedures, imaging and treatment
http://orcid.org/0000-0002-5592-1267
Lindén Magnus magnus.linden@regionhalland.se
magnus.linden@gu.se

12
Rosenblad Therese 34
Rosenborg Karin 5
Hansson Sverker 26
Brandström Per 26
1 grid.413537.7 0000 0004 0540 7520 Department of Pediatrics, Halland Hospital, Halmstad, Sweden
2 https://ror.org/01tm6cn81 grid.8761.8 0000 0000 9919 9582 Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
3 Department of Pediatrics, Lund Children’s Hospital, Lund, Sweden
4 https://ror.org/012a77v79 grid.4514.4 0000 0001 0930 2361 Division of Microbiology, Immunology and Glycobiology, Institute of Laboratory Medicine, Lund University, Lund, Sweden
5 grid.416452.0 Sachs’ Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden
6 grid.415579.b 0000 0004 0622 1824 Pediatric Uro-Nephrology Center, The Queen Silvia Children’s Hospital, Gothenburg, Sweden
15 7 2024
15 7 2024
2024
39 11 32513262
15 2 2024
29 4 2024
15 5 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

Urinary tract infection (UTI) in infants is a common, potentially life-threatening bacterial infection, and must be managed carefully through the entire chain of care from diagnosis, choice of treatment, follow-up and risk stratification of future complications. This Swedish nationwide study of infant UTI was conducted to evaluate the current management of infant UTI, yield of investigations and the Swedish UTI guidelines’ ability to detect abnormalities of importance in the urinary tract.

Methods

Infants < 1 year with a first episode of UTI were included in a prospective multicenter study. Treatment and follow-up were provided by local pediatricians. Clinical and laboratory findings and imaging results were reported to the coordinating center. The current management and results were compared with a previous Swedish study.

Results

One thousand three hundred six infants were included. Urine sampling was performed with clean catch technique in 93% of patients. Initial oral antibiotic treatment was used in 63%, predominantly third generation cephalosporines. Permanent kidney abnormalities were found in 10% and dilating vesicoureteral reflux (VUR) in 8%. Higher rates of male gender, non-E. coli infection and ultrasound dilatation were seen in infants < 1 month. UTI recurrences were reported in 18%.

Conclusions

Infant UTI is still generating a considerable amount of follow-up examinations. There is a significant shift towards clean catch as the main urine sampling method. Voiding cystourethrography is performed less frequently reducing the findings of low grade VUR. The incidence of renal scarring is comparable with earlier studies which suggests that the Swedish guidelines are able to identify individuals with risk for long-term complications.

Graphical abstract

A higher resolution version of the Graphical abstract is available as Supplementary information

Supplementary Information

The online version contains supplementary material available at 10.1007/s00467-024-06415-4.

Keywords

Urinary tract infection
Infant
Urine sampling
Vesicoureteral reflux
Clinical guidelines
Kidney damage
http://dx.doi.org/10.13039/501100009777 Region Halland http://dx.doi.org/10.13039/501100009780 Region Skåne http://dx.doi.org/10.13039/501100021548 Drottning Silvias barnsjukhus http://dx.doi.org/10.13039/501100007687 Svenska Läkaresällskapet http://dx.doi.org/10.13039/501100005689 Göteborgs Läkaresällskap http://dx.doi.org/10.13039/501100008035 Njurfonden http://dx.doi.org/10.13039/100017138 Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland University of GothenburgOpen access funding provided by University of Gothenburg.

issue-copyright-statement© International Pediatric Nephrology Association 2024
==== Body
pmcIntroduction

Urinary tract infections (UTIs) are among the most common bacterial infections in childhood, affecting 2% of infants, creating a high number of patients to be treated throughout pediatric emergency units [1]. Diagnostic procedures are especially challenging during the first year of life, as symptoms and signs of disease are unspecific. Prompt treatment and investigations to identify children at risk of short and long-term complications are recommended in guidelines from different countries and various professional bodies around the world [2–7]. The burden of post infection examinations, however, has been considerable and the optimal algorithm to investigate young children with UTI and how to predict future risk of kidney-related morbidity are still matters of debate.

Children with vesicoureteral reflux (VUR) or other congenital anomalies of the kidneys and urinary tract are more prone to febrile UTIs. However, the majority of infants with febrile UTI do not have VUR or malformations and their UTI susceptibility is not fully understood. A subset of infants with a first UTI develop recurrent infections (14–21%), with increased risk of acquired kidney damage [8–11]. The rate of recurrent UTI is as high as over 50% in children with certain risk factors such as bladder and bowel dysfunction and dilating VUR [12, 13]. While historically much effort was put into detecting VUR after a first febrile UTI, focus has now shifted towards identifying susceptibility factors associated with severe acute infections, recurrent UTIs and renal scarring [14, 15].

The current national Swedish guidelines for management of children with febrile UTI launched in 2013 were aimed to reduce radiologic imaging in children under 2 years of age and, in particular, the number of voiding cystourethrographies (VCUGs) [16]. Reducing the investigations of infants with a first febrile UTI, however, may increase the risk of not identifying children at risk of kidney related morbidity or anomalies of the urinary tract.

The primary purpose of this paper was to give an updated overview of infant UTI management in Sweden, by describing the study population, the basis of diagnosis, bacterial findings and antimicrobial resistance, treatment, imaging findings and recurrence rate. A secondary purpose was to evaluate the current clinical guidelines and their ability to detect high grade VUR and permanent kidney damage.

Patients and methods

We performed a prospective, observational, nationwide multicenter study of infant UTI in Sweden. All pediatric departments in the country were invited to participate and 29 out of 33 centers contributed to patient recruitment between March 20, 2017 and September 30, 2019. Infants < 1 year of age presenting with a first episode of suspected UTI were eligible for inclusion at the initiation of antibiotic treatment. Exclusion criteria were previous UTI, myelomeningocele, ongoing bladder catheterization and overt urogenital malformations. The diagnostic evaluation, treatment and further management were based on clinical judgement of the managing physician supported by the Swedish national guidelines. If the presumptive UTI diagnosis was abandoned after inclusion, the case was excluded. Infants with negative urine culture, missing culture or with mixed bacterial growth, yet treated as UTI, were also excluded but described below in a separate analysis.

A clinical report form was used for clinical data and patient characteristics from the acute episode including maximum recorded temperature, duration of fever (days) prior to starting treatment, circumcision status (boys), type of antibiotic treatment and administration mode, and results from investigations. A second report was registered 1 year after the index UTI including information on recurrent febrile UTIs, use and duration of antimicrobial prophylaxis and further imaging performed after the initial investigations.

According to the Swedish pediatric UTI guidelines, basic investigation included urine dipstick, urine culture, plasma creatinine, C-reactive protein (CRP) and renal and bladder ultrasonography (RBUS). Empiric treatment was recommended to commence intravenously with a third-generation cephalosporin and/or an aminoglycoside in severely ill children or those unable to take oral treatment. All other children were recommended an oral third generation cephalosporin, while trimethoprim/sulphamethoxazole was to be used only after the resistance pattern was known. An antibiotic course of 10 days was recommended in febrile UTI. Risk factors guiding further imaging of the urinary tract in infants were CRP ≥ 70 mg/L, creatinine > 30 µmol/L, non-E. coli infection and dilatation on RBUS with anteroposterior diameter (APD) ≥ 10 mm. For infants with one or more risk factors, 99mTc-dimercaptosuccinic acid (DMSA) scintigraphy was recommended to detect kidney involvement and/or congenital anomalies, and a follow-up DMSA scan for detection of permanent kidney injury in those with abnormal findings on the initial DMSA. 99mTc-mercaptoacetyltriglycine (MAG3) renography was used in some infants with dilatation of renal pelvis or ureter on RBUS. VCUG was limited to infants with dilatation on RBUS or uptake defects on DMSA scintigraphy.

Laboratory tests

Blood and urine samples were analyzed at the local clinical laboratories and included plasma or serum CRP (maximum reported value during the acute phase of infection), plasma creatinine, urine dip stick results for nitrite and leukocyte esterase. A urine leukocyte esterase (U-Le) test was graded 0–4, where ≥ 1 + , corresponding to ≥ 15 cells/µL, was considered as pyuria.

Urine sampling methods were reported as suprapubic aspiration (SPA), catheter, clean catch or bag sample and urine cultures by bacterial species and number of colony forming units (CFUs) in intervals of < 10,000, 10,000 to < 100,000 and ≥ 100,000 CFU/mL. Antimicrobial resistance to trimethoprim, nitrofurantoin, mecillinam, ceftibuten, cefadroxil or other antibiotics was reported.

Imaging studies

Imaging studies (RBUS, VCUG, DMSA and MAG3 scans) were performed at the local hospital and reported to the coordinating center. DMSA scans were considered abnormal when a focal uptake defect was detected or a relative function was below 45%. If both kidneys were affected, the kidney with the lowest relative function was used to characterize the patient. An abnormal DMSA scan 6 months or more after the index UTI was used to diagnose permanent kidney damage. Infants with a normal first DMSA scan and without recurrences were considered to have normal kidneys at follow-up [17]. When MAG3 renography was used, it was assessed with the same criteria.

VUR detected on VCUG was graded 1–5 according to recommendations by the International Reflux Study in Children [18]. In case of bilateral VUR, the highest grade was used to characterize the patient.

Statistics

Statistical analyses were performed using SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA). For normally distributed variables, mean and standard deviation were presented as descriptive data, for skewed variables median and interquartile range (IQR) were presented, and frequency and percent for categorical variables. Fisher’s exact test was used to compare two groups with dichotomous variables; the χ2 test was used for non-ordered categorical variables; Mantel–Haenszel χ2 trend test for ordered categorical variables, a two-sample t-test for normally distributed continuous variables and a Mann–Whitney U-test for skewed continuous variables. Univariable and multivariable logistic regression, based on forward selection, was applied when studying risk factors for recurrent UTI. Odds ratios (OR) with 95% CI and associated p-values are presented. The prediction ability was described by area under the receiver operating characteristic (ROC) curve, called c-statistics. All tests were 2-tailed and evaluated at the 0.05 significance level following a Bonferroni–Holm adjustment.

Results

The study enrolled 1454 infants (Fig. 1). Ninety-seven infants (7%) were diagnosed with other conditions and 1357 were judged and treated as having UTI by the managing pediatrician. Of the infants managed as UTI by the clinician, 25 were considered to have UTI despite negative urine cultures, in 20 cases urine culture was missing and in six there was mixed growth. The remaining 1306 (96%) cases were confirmed as UTI with positive urine cultures, constituting the population for further analysis. There were 601 boys (46%) with a median age of 2.7 months (IQR 1.3 to 4.7) and 705 girls (54%) with a median age of 5.6 months (IQR 2.9 to 8.4), p < 0.001. There was a male predominance in the first 4 months of life, thereafter UTI was more frequent in girls. Circumcision was reported in one boy.Fig. 1 Flow diagram of the study population

Character of UTI

The demographics and clinical and laboratory data for boys and girls, respectively, are shown in Table 1. Maximum temperature during the acute phase of infection was recorded in 1270 patients and fever ≥ 38 °C was reported in 1190 infants (94%). Mean temperatures for boys and girls were 39.0 C° (± 0.9) and 39.3 C° (± 0.9), respectively (p < 0.001). The duration of fever before initiation of treatment increased with age (p < 0.001) and was less than 1 day in 26% of the febrile patients (Fig. 2). Table 1 Demographics, clinical characteristics and laboratory findings at enrolment in 1306 infants with first time UTI

	Total	Boys n = 601 (46%)	Girls n = 705 (54%)	p-value	
Age in months

median (IQR)

	4.0 (2.0–7.0)

n = 1306

	2.7 (1.3–4.7)	5.6 (2.9–8.4)	 < 0.001*	
Temperature (°C)

mean (std)

	39.2 (0.9)

n = 1270

	39.0 (0.9)	39.3 (0.9)	 < 0.001*	
Urine sampling method	 n=1243			0.33	
 Clean catch	1150 (92.5%)	524 (92.1%)	626 (92.9%)		
 SPA	62 (5.0%)	34 (6.0%)	28 (4.2%)		
 Cath	20 (1.6%)	7 (1.2%)	13 (1.9%)		
 Bag	11 (0.9%)	4 (0.7%)	7 (1.0%)		
U-nitrite positive	499 (38.5%),

n = 1295

	227 (38.2%)	272 (38.9%)	0.819	
Pyuria (U-Le positive ≥ 1 +)	1263 (97.4%)	578 (96.5%)	685 (98.1%)	0.081	
U-Le-test 0	34 (2.6%)	21 (3.5%)	13 (1.9%)		
 + 	67 (5.2%)	31 (5.2%)	36 (5.2%)		
2 + 	271 (20.9%)	109 (18.2%)	162 (23.2%)		
3 + 	441 (34.0%)	197 (32.9%)	244 (35.0%)		
4 + 	484 (37.3%)

n = 1297

	241 (40.2%)	243 (34.8%)		
CRP (mg/L)

median (IQR)

	62 (28–109)

n = 1294

	58 (26–99)	67 (29–118)	0.003	
Creatinine (µmol/L)

median (IQR)

	21 (18–24)

n = 1256

	21 (18–25)	20 (17–24)	 < 0.001*	
Creatinine > 30 µmol/L	79 (6.3%)

n = 1256

	46 (7.9%)	33 (4.9%)	0.027	
IQR Interquartile range, std standard deviation, SPA suprapubic aspiration, Cath catheter, U-Le urine leukocyte esterase, CRP C-reactive protein

*Significant following Bonferroni-Holm adjustment

Fig. 2 Fever duration prior to start of treatment, according to age in 1169 infants with febrile UTI (p < 0.001, significant following Bonferroni–Holm adjustment)

Sampling method and urinalysis

Data on the urine sampling method was obtained in 1243 cases. A clean catch specimen was used in 1150 (92.5%), SPA in 62 (5.0%), catheter in 20 (1.6%) and collecting bag in 11 (0.9%). SPA was rarely performed except in the two largest centers. There were no significant differences between sampling methods regarding urine nitrite test, pyuria, bacterial numbers or proportion of non-E. coli.

A U-Le test was reported positive in 1263/1297 cases (97.4%) while nitrite was positive in 499/1295 cases (38.5%), both with no significant gender difference (p = 0.081 and p = 0.819, respectively).

Bacterial typing and antimicrobial sensitivity

Data on bacterial counts, available in 1301 urine cultures, showed 1058 (81%) with ≥ 100,000 CFU/mL, 201 (15%) with 10,000 to < 100,000 CFU/mL and 42 (3%) with < 10,000 CFU/mL. The predominating bacterial species was E. coli, reported in 1169 infants (90%). Data on bacteria and the corresponding findings in laboratory parameters and RBUS are summarized in Table 2. There were significant differences in bacterial counts, CRP level, rate of positive nitrite, pyuria, creatinine > 30 µmol/L and rate of dilatation on RBUS between infants with E. coli and non-E. coli infections. The higher grade of pyuria correlated with the higher bacterial count (Fig. 3). Table 2 Bacterial species in urine cultures, gender, age, laboratory findings and collecting system dilatation on RBUS in 1306 infants with E. coli and non-E. coli UTI

	E. coli n = 1169 (90%)	Non-E. coli n = 137 (10%)	p-value	
Non-E. coli isolates		Klebsiella 69 (5.3%)

Enterococcus faecalis 18 (1.4%)

Enterobacter 15 (1.1%)

Citrobacter 13 (1.0%)

Group B streptococcus 10 (0.8%)

Othera 12 (0.9%)

		
Gender boy/girl	529 (45.3%)/640 (54.7%)	72 (52.6%)/65 (47.4%)	0.123	
Age at UTI, months

median (IQR)

	4.1 (2.1–7.1)	3.1 (1.8–5.6)	0.002	
Nitrite positive	469/1158 (40.5%)	30/137 (21.9%)	 < 0.001*	
U-Le positive	1140/1161 (98.2%)	123/136 (90.4%)	 < 0.001*	
Bacterial count ≥ 100,000 CFU/mL	960/1165 (82.4%)	98/136 (72.1%)	0.005	
CRP median (mg/L)

(IQR)

	64 (n = 1158)

(31–110)

	46 (n = 136)

(10–99)

	0.001*	
Creatinine median (µmol/L)

(IQR)

	20 (n = 1125)

(18–24)

	22 (n = 131)

(19–27)

	 < 0.001*	
Creatinine > 30 µmol/L	59/1125 (5.2%)	20/131 (15.3%)	 < 0.001*	
Dilatation on RBUS	138/1163 (11.9%)	42/137 (30.7%)	 < 0.001*	
IQR, Interquartile range; U-Le, urine leukocyte esterase; CRP, C-reactive protein; RBUS, renal and bladder ultrasound

aProteus mirabilis 4, Aerococcus urinae 2, Staphylococcus aureus 2, Coagulase-negative staphylococcus 2, Haemophilus influenzae 1, Pseudomonas aeruginosa 1

*Significant following Bonferroni–Holm adjustment

Fig. 3 Grade of pyuria on urine leukocyte esterase test according to bacterial number in urine culture in 1293 infants. 1 + corresponds to ≥ 15 cells/µL (p < 0.001, significant following Bonferroni–Holm adjustment)

Trimethoprim resistance was detected in 22% of the E. coli isolates, followed by amoxicillin/clavulanic acid 8%, cefadroxil 4%, ceftibuten 2%, mecillinam 2%, and nitrofurantoin 0.2%. Extended spectrum beta-lactamase production (ESBL) was found in 4%.

Blood tests

The median CRP was 62 mg/L (IQR 28 to 109) and was higher in girls than in boys, 67 mg/L (IQR 29 to 118) and 58 mg/L (IQR 26 to 99), respectively (p = 0.003). Creatinine > 30 µmol/L was seen more often in boys, 46/579 (7.9%), than in girls, 33/677 (4.9%), p = 0.027, see Table 1.

Treatment

Treatment was initiated with intravenous antibiotics in 484 of 1305 patients (37%, information missing in one patient) and oral antibiotics in 821 (63%) of which 22 (3%) were temporarily switched to intravenous treatment. The use of initial oral antibiotics varied between centers and was higher in the two largest centers, 84% and 82% respectively, compared to 54% among the remaining centers. The younger infants were treated with intravenous antibiotics more frequently than the older ones: < 1 month 72%, 1– < 3 months 53%, 3– < 6 months 28% and 6– < 12 months 23% (p < 0.001). Initial intravenous treatment was changed to oral within three days in 82% of the cases. A change from the initial antibiotic therapy due to antimicrobial resistance was reported in 30 patients (2%).

The three most commonly used oral antibiotics as first line treatment were third generation cephalosporines in 718 (87%), trimethoprim/sulfamethoxazole in 77 (9%) and amoxicillin/clavulanic acid in 9 (1%). Among the initially intravenously treated infants, cefotaxime was used in 469 patients (97%) either as single therapy or combined with another agent (22 patients).

Imaging of the urinary tract

Ultrasound

RBUS was performed in 1300/1306 infants. The APD of the pelvis was not consistently reported. However, dilatation of the urinary tract was reported in 180 infants (14%), more frequently in boys, 115/598 (19%), than in girls, 65/702 (9%), p < 0.001. Bilateral dilatation was reported in 35 infants (3%). Kidney duplication was seen in 22 cases, multicystic dysplasia in three, unilateral aplastic kidney and horseshoe kidney in two each, and crossed kidney ectopia and kidney tumor in one each.

VCUG

VCUG was performed in 390 infants (30%) and VUR was detected in 147 (38%) of these; grade 1 in 10 (3%), grade 2 in 27 (7%), grade 3 in 32 (8%), grade 4 in 55 (14%) and grade 5 in 23 infants (6%). VUR grade 3–5 was more frequent in infants with dilatation on RBUS than without dilatation, 49/136 (36%) vs. 61/254 (24%), p = 0.013, not significant following Bonferroni–Holm adjustment. However, 61/110 (56%) of infants with VUR grade 3–5 had no dilatation on RBUS. Of the 23 infants with VUR grade 5, seven (30%) had no dilatation on RBUS. Bilateral dilating VUR was found in 40 infants and posterior urethral valves in seven boys.

Scintigraphy

Scintigraphy was performed in 836 infants (774 DMSA and 62 MAG3 scans) of which five were performed prior to the first UTI due to antenatally diagnosed hydronephrosis and 363 within 30 days after the acute infection. Among these 363 scans, 148 (41%) were abnormal. In 213 infants, at least one more scintigraphy was performed during follow-up. Scintigraphy data for evaluation of permanent kidney defects after 6 months was available in 648 infants, of which 126 (19%) were abnormal (33 of the follow-up scans were MAG3). Among these infants, five had bilateral damage. The degree of kidney impairment categorized by the relative function of the most affected kidney was more severe in boys than in girls (p < 0.001), Fig. 4. There was no difference in the rate of permanent kidney damage between infants with intravenous antibiotic treatment, 70/316 (22%), and oral treatment only, 56/332 (17%), p = 0.092.Fig. 4 Relative function of most affected kidney in (a) 66 boys compared to (b) 60 girls with permanent kidney damage on DMSA or MAG3 scintigraphy. In five cases of bilateral damage, the most severely affected kidney is presented (p < 0.001, significant following Bonferroni–Holm adjustment)

Follow-up after first UTI

At least one recurrent febrile UTI episode was reported in 229/1290 infants (18%), 86 (14%) boys and 143 (21%) girls. Significant risk factors for recurrent UTI following Bonferroni-Holm adjustment were non-E. coli bacteria at first UTI and dilatation on RBUS. In the multivariable model, female sex and dilatation on RBUS were independent risk factors, see Table 3. Table 3 Univariable and multivariable logistic regression of risk factors for febrile recurrent UTI a. Total recurrence rate 18%

	Univariable models	Multivariable model	
Variable	Values	Missing data	n (%) events	OR (95% CI)	p-value	AUC	OR (95% CI)	p-value	
Age in months

(by 1 month increase)

	 ≤ median	0	123 (18.9%)						
 > median	0	106 (16.6%)	0.97 (0.93–1.02)	0.23	0.52	0.94 (0.89–0.99)	0.014	
Sex	Boys	0	86 (14.4%)	Ref			Ref		
Girls	0	143 (20.6%)	1.54 (1.15–2.07)	0.0037	0.55	2.07 (1.49–2.88)	 < .0001*	
Bacteria at first UTI	E. coli	0	189 (16.4%)	Ref			Ref		
Non-E. coli	0	40 (29.4%)	2.13 (1.43–3.18)	0.0002*	0.54	1.83 (1.20–2.79)	0.0053	
Dilatation on RBUS (ref No)	No	6	170 (15.4%)	Ref			Ref		
Yes	6	59 (33.0%)	2.70 (1.90–3.84)	 < .0001*	0.57	2.77 (1.91–4.02)	 < .0001*	
CRP (mg/L)

(by 1 mg/dL increase)

	 ≤ median	12	98 (15.2%)						
 > median	12	130 (20.5%)	1.00 (1.00–1.00)	0.10	0.56			
CRP (mg/L)	CRP < 70	12	108 (15.2%)	Ref			Ref		
CRP ≥ 70	12	120 (21.1%)	1.49 (1.12–1.99)	0.0062	0.55	1.51 (1.12–2.04)	0.0065	
rUTI, recurrent urinary tract infection; RBUS, renal and bladder ultrasound; CRP, C-reactive protein; OR, odds ratio; CI, confidence interval; AUC, area under the curve

aData on recurrent UTI missing in 16 infants

*Significant following Bonferroni–Holm adjustment. Area under receiver operating characteristic curve (AUC) for the multivariable model was 0.66

Antimicrobial prophylaxis was prescribed to 237 of 1293 infants (18%), 29 (2%) for < 2 months and 206 (16%, 112 boys and 94 girls) for ≥ 2 months (no information on duration in two). Surgical interventions by a pediatric urologist were performed in 60 patients, for details see the Supplementary Table S1. One death was reported during the study period in conjunction with a recurrent UTI.

Influence of age

There were 140 children below 1 month of age included in the study. They differed in many aspects compared to older infants, with a pronounced male predominance, lower temperature, higher rate of non-E. coli, higher creatinine and a higher rate of dilation on RBUS, Table 4. The gender difference in the total study population with a higher rate of raised creatinine in boys was not seen when infants < 1 month were excluded. Table 4 Clinical, laboratory and imaging findings related to age

	 < 1 montha
n = 140	 ≥ 1 month
n = 1166	p-value	
Male (%)	112 (80.0%)	489 (41.9%)	 < 0.001	
Temperature ≥ 38°C	120/138 (87.0%)	1070/1132 (95.5%)	0.002	
Urine sampling method	
 Clean catch	106 (82.8%)	1044 (93.6%)		
 SPA	15 (11.7%)	47 (4.2%)		
 Catheter	3 (2.3%)	17 (1.5%)		
 Bag	4 (3.1%)

n = 128

	7 (0.6%)

n = 1115

		
Nitrite positive	58/139 (41.7%)	441/1156 (38.1%)	0.408	
U-Le positive (≥ 1 +)	130 (92.9%)	1133/1157 (97.9%)	0.002	
Non-E. coli	22 (15.7%)	115 (9.9%)	0.040	
Bacterial count ≥ 100,000 CFU/mL	119/138 (86.2%)	939/1163 (80.7%)	0.133	
CRP (mg/L)

Median (IQR)

	59.5 (24–102)	63 (28–110)

n = 1154

	0.236	
Creatinine > 30 µmol/L	34/137 (24.8%)	45/1119 (4.0%)	 < 0.001	
Intravenous antibiotics	101 (72.1%)	405/1165 (34.8%)	 < 0.001	
Dilatation on RBUS	30 (21.4%)	150/1160 (12.9%)	 < 0.001	
VUR grade 3–5	17/57 (29.8%)	93/333 (27.9%)	0.752	
Abnormal kidney scan six months after initial UTI	18/84 (21.4%)	108/564 (19.1%)	0.658	
SPA suprapubic aspiration, U-Le urine leukocyte esterase, CRP C-reactive protein, IQR interquartile range, RBUS renal and bladder ultrasound, VUR vesicoureteral reflux

aAge in days: median 19, minimum 5, IQR 11

Separate analysis of infants without confirmative urine culture

In 25 infants treated and managed as having UTI, the urine culture yielded no bacterial growth. These children were severely ill and in the majority antibiotic treatment was given before urine sampling. A comparison between these infants and those with bacterial growth of a single pathogen is shown in Table 5. The group with negative urine culture were younger and had a higher rate of creatinine > 30 µmol/L and dilatation on RBUS than the culture positive group. Among these 25 infants, two were subject to heminephrectomy due to obstruction and two had endoscopic treatment for dilating VUR and recurrent UTIs. For the 26 patients excluded due to urine culture missing or showing mixed growth, but treated as UTI, there were no such differences compared to the study population. Table 5 Clinical and laboratory parameters and imaging studies in infants with culture verified vs. culture negative UTI and vs. infants with missing culture (n = 20) or mixed growth (n = 6), yet treated as UTI

	Culture pos
n = 1306	Culture neg
n = 25	Culture missing or mixed growth
n = 26	p-valuea	p-valueb	
Male	601 (46%)	17 (68%)	11 (42%)	0.041	0.843	
Age median (months) (IQR)	4.0

(2.0–7.0)

	1.5

(0.9–2.8)

	3.8

(2.9–5.9)

	 < 0.001*	0.830	
Temperature (°C)

mean (std)

	39.2 (0.9)

n = 1270

	38.7 (0.7)

n = 24

	39.1 (0.9)

n = 24

	0.014	0.798	
U-nitrite pos	499/1295 (39%)	12/24 (50%)	10 (39%)	0.292	1.000	
CRP median (mg/L)

(IQR)

	62

(28–109)

n = 1294

	79

(52–107)

	66

(50–112)

	0.081	0.413	
Creatinine > 30 µmol/L	79/1256 (6.3%)	7/23 (30%)	3 (12%)	 < 0.001*	0.229	
Dilatation on RBUS	180/1300 (14%)	10 (40%)	5 (19%)	0.001*	0.394	
VUR grade 3–5	110/390 (28%)	7/14 (50%)	2/8 (25%)	0.128	1.000	
Abnormal kidney scan 6 months after initial UTI	126/648 (19%)	4/11 (36%)	1/12 (8%)	0.241	0.478	
IQR, interquartile range; std, standard deviation; CRP, C-reactive protein; IV, intravenous; RBUS, renal and bladder ultrasound; VUR, vesicoureteral reflux

ap-value in culture neg vs. culture pos

bp-value in culture missing or mixed growth vs. culture pos

*Significant following Bonferroni–Holm adjustment

Discussion

This nationwide study of 1306 infants with UTI provides a comprehensive overview of current diagnostic procedures, treatment, and management in Swedish pediatric care. According to national recommendations, infants with a suspected UTI are referred to and managed by pediatricians and we believe that the study population is representative for this age group.

Compared to the Swedish quality assurance project in the mid-1990s, a nationwide study of children < 2 years with first time UTI, our study revealed a remarkable shift in urine sampling method in favor of the clean catch technique, practiced in 93% of cases compared to only 11% in the 1990s, while bag samples, previously used in 50% of urine cultures, have virtually disappeared [19]. Bag samples, known to carry a high risk of contamination, are rarely used nowadays. However, it is surprising that SPA was infrequently performed in this population of young infants despite being recommended in the national guidelines. Clearly, clean catch urine has become the method of choice in pediatric specialist care in Sweden, a trend seen also in other parts of the world. This sampling technique has been proposed as an alternative to invasive techniques for infants in good clinical condition by the Italian, Indian, Australian and Swiss guidelines [5, 7, 20, 21] and is the recommended method in the NICE guidelines [2]. Clean catch urine combined with a standardized stimulation technique has shown similar contamination risk as urethral catheterization [22] while others advocate SPA or catheter specimens to avoid contamination [23].

Similar to other reports, we found non-E. coli in 10% of the infants, with comparable rates of Enterococcus and Klebsiella species, known to be associated with lower bacterial counts and less pyuria [24–26]. Eighteen percent of infants in our cohort had bacterial numbers less than 100,000 CFU/mL. This was in line with the frequency of 19–20% found in other studies [27–29]. These results indicate that disregarding urine cultures with low bacterial counts or low-grade pyuria in this age group could lead to a missed or delayed diagnosis and treatment.

From an international perspective, our study showed a low frequency of resistant uropathogens. A meta-analysis of antimicrobial resistance in children 0–5 years treated for UTI in primary care showed that the pooled prevalence of resistance in E. coli isolates was 29.8% for trimethoprim sulphamethoxazole, 9.6% for amoxicillin/clavulanic acid, and 4.9% for third generation cephalosporins [30].

Initial intravenous treatment was given to 37% of infants and was more frequent in younger age groups. Although 40% of the study subjects were younger than 3 months, we anticipated a more frequent use of oral antibiotics as initial treatment. The use of oral antibiotics for UTI in Swedish pediatric care has not changed since the 1990s despite evidence of oral antibiotic treatment being equally effective as intravenous administration in well appearing children [31, 32]. In the former Swedish study, the proportions of initial intravenous treatment in age groups 0– < 3 months, 3– < 6 months and 6– < 12 months were 51%, 31% and 24%, respectively, and in the current study 56%, 28%, and 21% [19]. In our study, there were similar rates of permanent kidney damage between oral and intravenous treatment groups, thereby supporting the evidence of safe oral antibiotic treatment in infant UTI. The practice of initial empirical treatment with oral antibiotics in infants in our study, however, was in sharp contrast to the standard practice of care in Japan. This was presented in a recent study on children aged < 36 months with UTI where almost all patients were hospitalized and initially treated with intravenous antibiotics and 81% of the patients were switched to oral antibiotics as late as day 4 to 8 of hospitalization [33].

Long-term antimicrobial prophylaxis was used in 16% of the patients, similar to the 1990s Swedish quality assurance study where it was used in 20% of the cases [19]. However, the use of prophylaxis while awaiting the initial imaging to be performed, has dropped from 79 to only 2%.

During the study period, prenatal ultrasound screening was offered to pregnant women at gestational week 12–14 (combined ultrasound and blood test for chromosomal anomalies) and week 18–19 (including organ screening) in most parts of the country. We did not ask for the information on any prenatal ultrasound in this study. Recommendations in the national UTI guidelines were to perform RBUS in all infants with first time UTI, justified by the need to identify children with major congenital abnormalities or obstruction of the kidneys and urinary tract. We used high creatinine as a risk factor that could indicate a more severely ill child with prerenal acute kidney injury, congenital hypo/dysplasia, known to be more common in boys, or kidneys that are more vulnerable to consequences of the infection. This should alert the caregiver to pay extra attention to that child and motivate further assessment and imaging.

Our study included a multivariable analysis of risk factors for recurrent UTI showing female gender as a significant independent risk factor. The higher recurrence rate in girls than in boys (21% vs. 14%) was in accordance with the Swedish reflux trial where recurrent UTIs were seen more frequently in girls (33%) than in boys (9%), although these children were all above 1 year of age [13]. Other studies on gender as a risk factor for recurrent UTI, however, are scarce and results not conclusive, partly due to small studies and diverging populations. A large pediatric primary care study by Conway et al. found no significant gender difference although children up to 6 years of age were included [34]. Neither could two smaller studies including younger children with first time UTI find significant differences in recurrence rate between males and females [35, 36].

The result of the Swedish quality assurance project [19] was a reflection of the management of infant UTI at that time, where most local guidelines were based on a bottom-up approach and kidney scarring was identified at follow-up with intravenous urography or DMSA scintigraphy. In comparison, we found a substantial reduction in the frequency of VCUGs in our study, 30% versus 85% in the 1990s. Furthermore, the use of intravenous urography has dropped from 25% of the patients to no urographies at all. On the other hand, 59% of children in our study were exposed to a DMSA scan, compared to 25% in the previous study and 13% had two DMSA scans during the study period. The radiation dose of a DMSA scan is approximately 0.7–1 mSv, equivalent to about 4–6 months of natural background radiation [37]. In light of the potential risks with exposure to ionizing radiation in early infancy it is prudent to continue the efforts of reducing the radiation burden for infants with UTI [38].

VUR grade 4 or 5, a major risk factor for scarring was detected in 78/1306 infants (6%) in our study population. In a meta-analysis by Shaik et al., where 1247 of 1280 children with a first UTI were examined by VCUG, 4% showed VUR grade 4 or 5 [39]. In a single center study of infants with UTI where VCUG was performed in all participants the detection rate of VUR grade 4 or 5 was 5% [40]. Our relatively high rate of VUR grade 4 and 5, despite only 30% of the cohort being subject to a VCUG indicates that the Swedish guidelines effectively identified infants with a high risk of dilating VUR.

Results from the DMSA and MAG3 scintigraphies identified permanent abnormalities of the kidneys in 126 of the 1306 infants (10%) which could result in further investigations or long-term follow-up. Since our study only had end point data for permanent kidney damage from 648 of the 1306 patients (50%) in the cohort, 10% is a minimum rate. Boys had significantly more severe kidney defects than girls. This yield is comparable to Hoberman et al., reporting 26 cases of renal damage after UTI in 275 children (9.5%) [17]. However, according to other studies, the expected rate of kidney scarring after a first UTI varies from 15 to up to 25% when discrete uptake defects on DMSA were also included [41, 42]. Furthermore, in a recent study of prophylaxis or no prophylaxis to infants with dilating VUR before any UTI, new parenchymal kidney defects occurred regardless of whether the children had a UTI or not during follow-up [43].

There were 25 infants excluded from the study, with no growth in the urine culture, yet diagnosed and treated as having UTI. Compared to the study population, these infants were younger and more likely to have affected kidney function by elevated creatinine (Table 4). Furthermore, dilatation on RBUS was more prevalent, as was dilating VUR and kidney damage although not reaching significance levels. These infants were reported to be ill appearing and, in the majority, a first dose of antibiotics was given prior to urine sampling. Thus, these infants comprise a clinically challenging group, although not fitting into the study requisite.

A limitation with the study was that imaging investigations and chemistry lab tests were analyzed and interpreted in the local laboratories with the risk of regional and individual differences or errors. There was no requirement of standardized protocol for the ultrasound examinations performed at the 29 different centers and reports often lacked data on APD. Yet, the rate of dilatation of the urinary tract in our study, 14%, was very similar to the 15% rate of dilatation found in a single center study with a standardized protocol on 290 infants with UTI [40].

The predominant use of clean catch urine sampling carries a risk of patients being included who did not suffer from a true UTI. In addition, as the guidelines did not define any specific limit for bacterial count, a few children with contaminated urine culture may have been falsely classified as having UTI. On the other hand, this makes the study more relevant for evaluating management and patient characteristics in every day clinical care of infants treated for UTI and evaluating the diagnostic yield, burden of investigations and functionality of clinical guidelines in routine pediatric practice.

From public demographic data and expected UTI incidence in infants, we estimate that there were roughly 5000 infants eligible for inclusion during the study period. However, there was no indication of systematic bias in the sample selection. A few centers in the country did not include any patients at all and when analyzing two of the largest centers, there was no difference in gender, age or temperature between the children included in the study and those not included.

In conclusion, this report describes current management of infants with first time UTI in pediatric centers in Sweden and provides data on the yield of the implemented investigations in a large and representative population. Since the 1990s, a major shift in urine collection method in favor of the clean catch technique was noted. Furthermore, the use of prophylactic antibiotics while awaiting investigation with VCUG, has virtually disappeared. Initial intravenous antibiotic treatment was surprisingly unchanged providing incentive for improvement by increased outpatient management or oral antibiotic use in inpatient care. This would render savings for the healthcare provider and less traumatic care.

The study results indicate that the Swedish UTI guidelines are able to identify important abnormalities such as permanent kidney damage and dilating VUR. We have reduced the number of VCUG considerably, however, the number of DMSA investigations on infants with UTI is still substantial. Our work continues with reducing the burden of investigations further, in particular radiation exposure, and developing individualized methods of risk assessment. The management of the very youngest infants should be more clearly addressed in future revisions of the guidelines.

Supplementary Information

Below is the link to the electronic supplementary material.Graphical abstract (PPTX 80 KB)

Supplementary file2 (DOCX 18 KB)

Acknowledgements

We thank Aldina Pivodic for help with statistical analysis and Tina Linnér for coordination. We would also like to extend our gratitude to the co-workers of this study in Borås, Eskilstuna, Falun, Gävle, Göteborg, Halmstad, Helsingborg, Hudiksvall, Jönköping, Kalmar, Karlskrona, Karlstad, Kristianstad, Luleå, Lund/Malmö, Skövde, Sollefteå, Stockholm/Karolinska sjukhuset, Stockholm/Sachsska Barnsjukhuset, Sundsvall, Trollhättan, Umeå, Uppsala, Visby, Västervik, Västerås, Växjö, Örebro, Östersund.

Funding

Open access funding provided by University of Gothenburg. The study was supported by grants from Region Halland and the Southern Healthcare Region, Sweden, the Queen Silvia Children’s Hospital Research Foundation, the Swedish Society of Medicine, the Gothenburg Society of Medicine, the Swedish kidney foundation, Bertil and Berit Adström’s foundation, Märtha and Gustaf Ågren’s foundation and the Operational Healthcare Committee, Region Västra Götaland.

Data availability

The data set generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the research ethics committee at Lund University (EPN 2015–884, 2016–799, 2017–164 and 2017–315) and with the 1964 Helsinki declaration and its later amendments.

Consent to participate

Written informed consent was obtained from all guardians to participants included in the study.

Competing interests

The authors declare no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Magnus Lindén and Therese Rosenblad contributed equally to this work.
==== Refs
References

1. Jakobsson B Esbjörner E Hansson S Association SPN Minimum incidence and diagnostic rate of first urinary tract infection Pediatrics 1999 104 222 226 10.1542/peds.104.2.222 10428998
Jakobsson B, Esbjörner E, Hansson S (1999) Minimum incidence and diagnostic rate of first urinary tract infection. Pediatrics 104:222–226. 10.1542/peds.104.2.22210428998
2. National Institute for Health and Care Excellence (2022) Urinary tract infection in under 16s: diagnosis and management. London. https://www.ncbi.nlm.nih.gov/books/NBK588844. Accessed 21 March 2024
3. Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and ManagementRoberts KB Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months Pediatrics 2011 128 595 610 10.1542/peds.2011-1330 21873693
Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management, Roberts KB (2011) Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics 128:595–610. 10.1542/peds.2011-133021873693
4. Stein R Dogan HS Hoebeke P Kočvara R Nijman RJM Radmayr C Tekgül S Urinary tract infections in children: EAU/ESPU guidelines Eur Urol 2015 67 546 558 10.1016/j.eururo.2014.11.007 25477258
Stein R, Dogan HS, Hoebeke P, Kočvara R, Nijman RJM, Radmayr C, Tekgül S (2015) Urinary tract infections in children: EAU/ESPU guidelines. Eur Urol 67:546–558. 10.1016/j.eururo.2014.11.00725477258
5. Ammenti A Alberici I Brugnara M Chimenz R Guarino S La Manna A La Scola C Maringhini S Marra G Materassi M Morello W Nicolini G Pennesi M Pisanello L Pugliese F Scozzola F Sica F Toffolo A Montini G Italian Society of Pediatric Nephrology Updated Italian recommendations for the diagnosis, treatment and follow-up of the first febrile urinary tract infection in young children Acta Paediatr 2020 109 236 247 10.1111/apa.14988 31454101
Ammenti A, Alberici I, Brugnara M, Chimenz R, Guarino S, La Manna A, La Scola C, Maringhini S, Marra G, Materassi M, Morello W, Nicolini G, Pennesi M, Pisanello L, Pugliese F, Scozzola F, Sica F, Toffolo A, Montini G, Italian Society of Pediatric Nephrology (2020) Updated Italian recommendations for the diagnosis, treatment and follow-up of the first febrile urinary tract infection in young children. Acta Paediatr 109:236–247. 10.1111/apa.1498831454101
6. Yang SS Tsai J-D Kanematsu A Han C-H Asian guidelines for urinary tract infection in children J Infect Chemother 2021 27 1543 1554 10.1016/j.jiac.2021.07.014 34391623
Yang SS, Tsai J-D, Kanematsu A, Han C-H (2021) Asian guidelines for urinary tract infection in children. J Infect Chemother 27:1543–1554. 10.1016/j.jiac.2021.07.01434391623
7. Hari P Meena J Kumar M Sinha A Thergaonkar RW Iyengar A Khandelwal P Ekambaram S Pais P Sharma J Kanitkar M Bagga A Bagga A Agarwal I Bajpai M Banerjee S Jana M Kalra S Kumar R Krishan A Krishnamurthy N Mishra K Mantan M Mehta A Ohri A Panchal B Priyadarshini S Raut S Saha A Sethi S Sinha R Thergoankar RW Uthup S Vasudev A Indian Society of Pediatric Nephrology Evidence-based clinical practice guideline for management of urinary tract infection and primary vesicoureteric reflux Pediatr Nephrol 2024 39 1639 1668 10.1007/s00467-023-06173-9 37897526
Hari P, Meena J, Kumar M, Sinha A, Thergaonkar RW, Iyengar A, Khandelwal P, Ekambaram S, Pais P, Sharma J, Kanitkar M, Bagga A, Bagga A, Agarwal I, Bajpai M, Banerjee S, Jana M, Kalra S, Kumar R, Krishan A, Krishnamurthy N, Mishra K, Mantan M, Mehta A, Ohri A, Panchal B, Priyadarshini S, Raut S, Saha A, Sethi S, Sinha R, Thergoankar RW, Uthup S, Vasudev A, Indian Society of Pediatric Nephrology (2024) Evidence-based clinical practice guideline for management of urinary tract infection and primary vesicoureteric reflux. Pediatr Nephrol 39:1639–1668. 10.1007/s00467-023-06173-937897526
8. Swerkersson S Jodal U Sixt R Stokland E Hansson S Urinary tract infection in small children: the evolution of renal damage over time Pediatr Nephrol 2017 32 1907 1913 10.1007/s00467-017-3705-5 28681079
Swerkersson S, Jodal U, Sixt R, Stokland E, Hansson S (2017) Urinary tract infection in small children: the evolution of renal damage over time. Pediatr Nephrol 32:1907–1913. 10.1007/s00467-017-3705-528681079
9. Williams G Craig JC Long-term antibiotics for preventing recurrent urinary tract infection in children Cochrane Database Syst Rev 2019 4 CD001534 10.1002/14651858.CD001534.pub4 30932167
Williams G, Craig JC (2019) Long-term antibiotics for preventing recurrent urinary tract infection in children. Cochrane Database Syst Rev 4:CD001534. 10.1002/14651858.CD001534.pub430932167
10. Hellerstein S Long-term consequences of urinary tract infections Curr Opin Pediatr 2000 12 125 128 10.1097/00008480-200004000-00007 10763761
Hellerstein S (2000) Long-term consequences of urinary tract infections. Curr Opin Pediatr 12:125–128. 10.1097/00008480-200004000-0000710763761
11. Shaikh N Haralam MA Kurs-Lasky M Hoberman A Association of renal scarring with number of febrile urinary tract infections in children JAMA Pediatr 2019 173 949 952 10.1001/jamapediatrics.2019.2504 31381021
Shaikh N, Haralam MA, Kurs-Lasky M, Hoberman A (2019) Association of renal scarring with number of febrile urinary tract infections in children. JAMA Pediatr 173:949–952. 10.1001/jamapediatrics.2019.250431381021
12. Keren R Shaikh N Pohl H Gravens-Mueller L Ivanova A Zaoutis L Patel M deBerardinis R Parker A Bhatnagar S Haralam MA Pope M Kearney D Sprague B Barrera R Viteri B Egigueron M Shah N Hoberman A Risk factors for recurrent urinary tract infection and renal scarring Pediatrics 2015 136 e13 e21 10.1542/peds.2015-0409 26055855
Keren R, Shaikh N, Pohl H, Gravens-Mueller L, Ivanova A, Zaoutis L, Patel M, deBerardinis R, Parker A, Bhatnagar S, Haralam MA, Pope M, Kearney D, Sprague B, Barrera R, Viteri B, Egigueron M, Shah N, Hoberman A (2015) Risk factors for recurrent urinary tract infection and renal scarring. Pediatrics 136:e13–e21. 10.1542/peds.2015-040926055855
13. Brandström P Esbjörner E Herthelius M Swerkersson S Jodal U Hansson S The Swedish Reflux Trial in Children: III Urinary tract infection pattern J Urol 2010 184 286 291 10.1016/j.juro.2010.01.061 20488494
Brandström P, Esbjörner E, Herthelius M, Swerkersson S, Jodal U, Hansson S (2010) The Swedish Reflux Trial in Children: III. Urinary tract infection pattern J Urol 184:286–291. 10.1016/j.juro.2010.01.06120488494
14. Ragnarsdóttir B Svanborg C Susceptibility to acute pyelonephritis or asymptomatic bacteriuria: host–pathogen interaction in urinary tract infections Pediatr Nephrol 2012 27 2017 2029 10.1007/s00467-011-2089-1 22327887
Ragnarsdóttir B, Svanborg C (2012) Susceptibility to acute pyelonephritis or asymptomatic bacteriuria: host–pathogen interaction in urinary tract infections. Pediatr Nephrol 27:2017–2029. 10.1007/s00467-011-2089-122327887
15. Kosmeri C Kalaitzidis R Siomou E An update on renal scarring after urinary tract infection in children: what are the risk factors? J Pediatr Urol 2019 15 598 603 10.1016/j.jpurol.2019.09.010 31591046
Kosmeri C, Kalaitzidis R, Siomou E (2019) An update on renal scarring after urinary tract infection in children: what are the risk factors? J Pediatr Urol 15:598–603. 10.1016/j.jpurol.2019.09.01031591046
16. Brandström P Lindén M How Swedish guidelines on urinary tract infections in children compare to Canadian, American and European guidelines Acta Paediatr 2021 110 1759 1771 10.1111/apa.15727 33341101
Brandström P, Lindén M (2021) How Swedish guidelines on urinary tract infections in children compare to Canadian, American and European guidelines. Acta Paediatr 110:1759–1771. 10.1111/apa.1572733341101
17. Hoberman A Charron M Hickey RW Baskin M Kearney DH Wald ER Imaging studies after a first febrile urinary tract infection in young children N Engl J Med 2003 348 195 202 10.1056/NEJMoa021698 12529459
Hoberman A, Charron M, Hickey RW, Baskin M, Kearney DH, Wald ER (2003) Imaging studies after a first febrile urinary tract infection in young children. N Engl J Med 348:195–202. 10.1056/NEJMoa02169812529459
18. Lebowitz RL Olbing H Parkkulainen KV Smellie JM Tamminen-Möbius TE International system of radiographic grading of vesicoureteric reflux. International reflux study in Children Pediatr Radiol 1985 15 105 109 10.1007/bf02388714 3975102
Lebowitz RL, Olbing H, Parkkulainen KV, Smellie JM, Tamminen-Möbius TE (1985) International system of radiographic grading of vesicoureteric reflux. International reflux study in Children. Pediatr Radiol 15:105–109. 10.1007/bf023887143975102
19. Hansson S Bollgren I Esbjörner E Jakobsson B Mårild S Association SPN Urinary tract infections in children below two years of age: a quality assurance project in Sweden Acta Paediatr 1999 88 270 274 10.1111/j.1651-2227.1999.tb01095.x 10229036
Hansson S, Bollgren I, Esbjörner E, Jakobsson B, Mårild S (1999) Urinary tract infections in children below two years of age: a quality assurance project in Sweden. Acta Paediatr 88:270–274. 10.1111/j.1651-2227.1999.tb01095.x10229036
20. McTaggart S Danchin M Ditchfield M Hewitt I Kausman J Kennedy S Trnka P Williams G KHA-CARI guideline: diagnosis and treatment of urinary tract infection in children Nephrology 2015 20 55 60 10.1111/nep.12349 25307259
McTaggart S, Danchin M, Ditchfield M, Hewitt I, Kausman J, Kennedy S, Trnka P, Williams G (2015) KHA-CARI guideline: diagnosis and treatment of urinary tract infection in children. Nephrology 20:55–60. 10.1111/nep.1234925307259
21. Buettcher M Trueck J Niederer-Loher A Heininger U Agyeman P Asner S Berger C Bielicki J Kahlert C Kottanattu L Meyer Sauteur PM Paioni P Posfay-Barbe K Relly C Ritz N Zimmermann P Zucol F Gobet R Shavit S Rudin C Laube G von Vigier R Neuhaus TJ Swiss consensus recommendations on urinary tract infections in children Eur J Pediatr 2021 180 663 674 10.1007/s00431-020-03714-4 32621135
Buettcher M, Trueck J, Niederer-Loher A, Heininger U, Agyeman P, Asner S, Berger C, Bielicki J, Kahlert C, Kottanattu L, Meyer Sauteur PM, Paioni P, Posfay-Barbe K, Relly C, Ritz N, Zimmermann P, Zucol F, Gobet R, Shavit S, Rudin C, Laube G, von Vigier R, Neuhaus TJ (2021) Swiss consensus recommendations on urinary tract infections in children. Eur J Pediatr 180:663–674. 10.1007/s00431-020-03714-432621135
22. Labrosse M Levy A Autmizguine J Gravel J Evaluation of a new strategy for clean-catch urine in infants Pediatrics 2016 138 e20160573 10.1542/peds.2016-0573 27542848
Labrosse M, Levy A, Autmizguine J, Gravel J (2016) Evaluation of a new strategy for clean-catch urine in infants. Pediatrics 138:e20160573. 10.1542/peds.2016-057327542848
23. Breinbjerg A Mohamed L Nielsen SY Rittig S Tullus K Kamperis K Pitfalls in diagnosing urinary tract infection in children below the age of 2: suprapubic aspiration vs clean-catch urine sampling J Urol 2021 206 1482 1489 10.1097/JU.0000000000002117 34288716
Breinbjerg A, Mohamed L, Nielsen SY, Rittig S, Tullus K, Kamperis K (2021) Pitfalls in diagnosing urinary tract infection in children below the age of 2: suprapubic aspiration vs clean-catch urine sampling. J Urol 206:1482–1489. 10.1097/JU.000000000000211734288716
24. Nadeem S Manuel MM Oke OK Patel V Filkins LM Badawy MK Park JY Hennes HM Association of pyuria with uropathogens in young children J Pediatr 2022 245 208 212.e202 10.1016/j.jpeds.2022.01.048 35120990
Nadeem S, Manuel MM, Oke OK, Patel V, Filkins LM, Badawy MK, Park JY, Hennes HM (2022) Association of pyuria with uropathogens in young children. J Pediatr 245:208-212.e202. 10.1016/j.jpeds.2022.01.04835120990
25. Shaikh N Shope TR Hoberman A Vigliotti A Kurs-Lasky M Martin JM Association between uropathogen and pyuria Pediatrics 2016 138 e20160087 10.1542/peds.2016-0087 27328921
Shaikh N, Shope TR, Hoberman A, Vigliotti A, Kurs-Lasky M, Martin JM (2016) Association between uropathogen and pyuria. Pediatrics 138:e20160087. 10.1542/peds.2016-008727328921
26. Ünsal H Kaman A Tanır G Relationship between urinalysis findings and responsible pathogens in children with urinary tract infections J Pediatr Urol 2019 15 606.e601 606.e606 10.1016/j.jpurol.2019.09.017
Ünsal H, Kaman A, Tanır G (2019) Relationship between urinalysis findings and responsible pathogens in children with urinary tract infections. J Pediatr Urol 15:606.e601-606.e606. 10.1016/j.jpurol.2019.09.017
27. Koskimies O Diagnostic accuracy of urinary tract infection and subsequent develpment of renal scars J Pediatr 1995 126 157 158 10.1016/S0022-3476(95)70532-5 7815212
Koskimies O (1995) Diagnostic accuracy of urinary tract infection and subsequent develpment of renal scars. J Pediatr 126:157–158. 10.1016/S0022-3476(95)70532-57815212
28. Hansson S Brandström P Jodal U Larsson P Low bacterial counts in infants with urinary tract infection J Pediatr 1998 132 180 182 10.1016/S0022-3476(98)70512-8 9470028
Hansson S, Brandström P, Jodal U, Larsson P (1998) Low bacterial counts in infants with urinary tract infection. J Pediatr 132:180–182. 10.1016/S0022-3476(98)70512-89470028
29. Swerkersson S Jodal U Åhrén C Sixt R Stokland E Hansson S Urinary tract infection in infants: the significance of low bacterial count Pediatr Nephrol 2016 31 239 245 10.1007/s00467-015-3199-y 26358231
Swerkersson S, Jodal U, Åhrén C, Sixt R, Stokland E, Hansson S (2016) Urinary tract infection in infants: the significance of low bacterial count. Pediatr Nephrol 31:239–245. 10.1007/s00467-015-3199-y26358231
30. Bryce A Hay AD Lane IF Thornton HV Wootton M Costelloe C Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis BMJ 2016 352 i939 10.1136/bmj.i939 26980184
Bryce A, Hay AD, Lane IF, Thornton HV, Wootton M, Costelloe C (2016) Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis. BMJ 352:i939. 10.1136/bmj.i93926980184
31. Montini G Toffolo A Zucchetta P Dall'Amico R Gobber D Calderan A Maschio F Pavanello L Molinari PP Scorrano D Zanchetta S Cassar W Brisotto P Corsini A Sartori S Dalt LD Murer L Zacchello G Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial BMJ 2007 335 386 10.1136/bmj.39244.692442.55 17611232
Montini G, Toffolo A, Zucchetta P, Dall’Amico R, Gobber D, Calderan A, Maschio F, Pavanello L, Molinari PP, Scorrano D, Zanchetta S, Cassar W, Brisotto P, Corsini A, Sartori S, Dalt LD, Murer L, Zacchello G (2007) Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial. BMJ 335:386. 10.1136/bmj.39244.692442.5517611232
32. Hoberman A Wald ER Hickey RW Baskin M Charron M Majd M Kearney DH Reynolds EA Ruley J Janosky JE Oral versus initial intravenous therapy for urinary tract infections in young febrile children Pediatrics 1999 104 79 86 10.1542/peds.104.1.79 10390264
Hoberman A, Wald ER, Hickey RW, Baskin M, Charron M, Majd M, Kearney DH, Reynolds EA, Ruley J, Janosky JE (1999) Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics 104:79–86. 10.1542/peds.104.1.7910390264
33. Okubo Y Uda K Miyairi I Michihata N Kumazawa R Matsui H Fushimi K Yasunaga H Nationwide epidemiology and clinical practice patterns of pediatric urinary tract infections: application of multivariate time-series clustering Pediatr Nephrol 2023 38 4033 4041 10.1007/s00467-023-06053-2 37382710
Okubo Y, Uda K, Miyairi I, Michihata N, Kumazawa R, Matsui H, Fushimi K, Yasunaga H (2023) Nationwide epidemiology and clinical practice patterns of pediatric urinary tract infections: application of multivariate time-series clustering. Pediatr Nephrol 38:4033–4041. 10.1007/s00467-023-06053-237382710
34. Conway PH Cnaan A Zaoutis T Henry BV Grundmeier RW Keren R Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials JAMA 2007 298 179 186 10.1001/jama.298.2.179 17622599
Conway PH, Cnaan A, Zaoutis T, Henry BV, Grundmeier RW, Keren R (2007) Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials. JAMA 298:179–186. 10.1001/jama.298.2.17917622599
35. Nuutinen M Uhari M Recurrence and follow-up after urinary tract infection under the age of 1 year Pediatr Nephrol 2001 16 69 72 10.1007/s004670000493 11198607
Nuutinen M, Uhari M (2001) Recurrence and follow-up after urinary tract infection under the age of 1 year. Pediatr Nephrol 16:69–72. 10.1007/s00467000049311198607
36. Panaretto K Craig J Knight J Howman-Giles R Sureshkumar P Roy L Risk factors for recurrent urinary tract infection in preschool children J Paediatr Child Health 1999 35 454 459 10.1046/j.1440-1754.1999.355417.x 10571758
Panaretto K, Craig J, Knight J, Howman-Giles R, Sureshkumar P, Roy L (1999) Risk factors for recurrent urinary tract infection in preschool children. J Paediatr Child Health 35:454–459. 10.1046/j.1440-1754.1999.355417.x10571758
37. Smith T Evans K Lythgoe MF Anderson PJ Gordon I Radiation dosimetry of technetium-99m-DMSA in children J Nucl Med 1996 37 1336 1342 8708767
Smith T, Evans K, Lythgoe MF, Anderson PJ, Gordon I (1996) Radiation dosimetry of technetium-99m-DMSA in children. J Nucl Med 37:1336–13428708767
38. Rajaraman P Simpson J Neta G Gonzalez ABd Ansell P Linet MS Ron E Roman E Early life exposure to diagnostic radiation and ultrasound scans and risk of childhood cancer: case-control study BMJ 2011 342 d472 10.1136/bmj.d472 21310791
Rajaraman P, Simpson J, Neta G, Gonzalez ABd, Ansell P, Linet MS, Ron E, Roman E (2011) Early life exposure to diagnostic radiation and ultrasound scans and risk of childhood cancer: case-control study. BMJ 342:d472. 10.1136/bmj.d47221310791
39. Shaikh N Hoberman A Rockette HE Kurs-Lasky M Identifying children with vesicoureteral reflux: a comparison of 2 approaches J Urol 2012 188 1895 1899 10.1016/j.juro.2012.07.013 22998917
Shaikh N, Hoberman A, Rockette HE, Kurs-Lasky M (2012) Identifying children with vesicoureteral reflux: a comparison of 2 approaches. J Urol 188:1895–1899. 10.1016/j.juro.2012.07.01322998917
40. Preda I Jodal U Sixt R Stokland E Hansson S Value of ultrasound in evaluation of infants with first urinary tract infection J Urol 2010 183 1984 1988 10.1016/j.juro.2010.01.032 20303537
Preda I, Jodal U, Sixt R, Stokland E, Hansson S (2010) Value of ultrasound in evaluation of infants with first urinary tract infection. J Urol 183:1984–1988. 10.1016/j.juro.2010.01.03220303537
41. Shaikh N Ewing AL Bhatnagar S Hoberman A Risk of renal scarring in children with a first urinary tract infection: a systematic review Pediatrics 2010 126 1084 1091 10.1542/peds.2010-0685 21059720
Shaikh N, Ewing AL, Bhatnagar S, Hoberman A (2010) Risk of renal scarring in children with a first urinary tract infection: a systematic review. Pediatrics 126:1084–1091. 10.1542/peds.2010-068521059720
42. Preda I Jodal U Sixt R Stokland E Hansson S Imaging strategy for infants with urinary tract infection: a new algorithm J Urol 2011 185 1046 1052 10.1016/j.juro.2010.10.043 21247606
Preda I, Jodal U, Sixt R, Stokland E, Hansson S (2011) Imaging strategy for infants with urinary tract infection: a new algorithm. J Urol 185:1046–1052. 10.1016/j.juro.2010.10.04321247606
43. Morello W Baskin E Jankauskiene A Yalcinkaya F Zurowska A Puccio G Serafinelli J Manna AL Krzemień G Pennesi M Scola CL Becherucci F Brugnara M Yuksel S Mekahli D Chimenz R Palma DD Zucchetta P Vajauskas D Drozdz D Szczepanska M Caliskan S Lombet J Minoli DG Guarino S Gulleroglu K Ruzgiene D Szmigielska A Barbi E Ozcakar ZB Kranz A Pasini A Materassi M Rechter SD Ariceta G Weber LT Marzuillo P Alberici I Taranta-Janusz K Afonso AC Tkaczyk M Català M Sevilla JEC Mehls O Schaefer F Montini G Antibiotic prophylaxis in infants with grade III, IV, or V vesicoureteral reflux N Engl J Med 2023 389 987 997 10.1056/NEJMoa2300161 37702442
Morello W, Baskin E, Jankauskiene A, Yalcinkaya F, Zurowska A, Puccio G, Serafinelli J, Manna AL, Krzemień G, Pennesi M, Scola CL, Becherucci F, Brugnara M, Yuksel S, Mekahli D, Chimenz R, Palma DD, Zucchetta P, Vajauskas D, Drozdz D, Szczepanska M, Caliskan S, Lombet J, Minoli DG, Guarino S, Gulleroglu K, Ruzgiene D, Szmigielska A, Barbi E, Ozcakar ZB, Kranz A, Pasini A, Materassi M, Rechter SD, Ariceta G, Weber LT, Marzuillo P, Alberici I, Taranta-Janusz K, Afonso AC, Tkaczyk M, Català M, Sevilla JEC, Mehls O, Schaefer F, Montini G (2023) Antibiotic prophylaxis in infants with grade III, IV, or V vesicoureteral reflux. N Engl J Med 389:987–997. 10.1056/NEJMoa230016137702442
